How does a strategy combining education, motivation and counselling affect outcomes in type 2 diabetes patients?

A randomized clinical trial to examine the levels of body mass index, fasting blood glucose, blood pressure and glycemic control using Multi-Modality Strategies among adults with type 2 diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14410756

Enrollment

200

Registered

2018-12-20

Start date

2015-06-02

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

Methodology used a randomized control trial (RCT) prospective interventional design, with an intervention group and control group in the study. The two-arm RCT was used to evaluate the effects of the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged =18 years 2. Met the medical diagnosis of type 2 diabetes 3. Counselled about anti-diabetic medications 4. Spoke and understood Arabic or English 5. Had been to the doctor in the last 2 years

Exclusion criteria

Exclusion criteria: 1. Complex health problems

Design outcomes

Primary

Measure	Time frame
1. Fasting blood glucose (FBS in mmol/L) was measured using reliable glucose meters and test strips regulated by the US Food and drug administration was used to ensure safety. One Touch Ultra2 System Kit 1 was used to test the fasting blood sugar levels after an overnight fast. A fasting sugar level less than 100 mg/dl (5.6 mmol/L) is normal and was taken an analysed in the laboratory. 2. Glycosylated haemoglobin (HbA1c in %) was used to monitor blood glucose control over a period of time, indicated an average blood sugar level for the past 2-3 months. An A1c level of 6.5% or higher on two separate tests indicated diabetes and was performed on a valid hemoglobin analyzer Quo-Lab HbA1c. 3. Systolic and diastolic blood pressure (SBP/DBP in mm Hg) was measured using an upper arm blood pressure monitor uA-767 Plus Omron’s valid monitor. 4. Body mass index (BMI in kg/m2) in ISI units was measured using a reliable height and weight instrument to balance from digital body height and weight scale.	—

Measure

Time frame

1. Fasting blood glucose (FBS in mmol/L) was measured using reliable glucose meters and test strips regulated by the US Food and drug administration was used to ensure safety. One Touch Ultra2 System Kit 1 was used to test the fasting blood sugar levels after an overnight fast. A fasting sugar level less than 100 mg/dl (5.6 mmol/L) is normal and was taken an analysed in the laboratory. 2. Glycosylated haemoglobin (HbA1c in %) was used to monitor blood glucose control over a period of time, indicated an average blood sugar level for the past 2-3 months. An A1c level of 6.5% or higher on two separate tests indicated diabetes and was performed on a valid hemoglobin analyzer Quo-Lab HbA1c. 3. Systolic and diastolic blood pressure (SBP/DBP in mm Hg) was measured using an upper arm blood pressure monitor uA-767 Plus Omron’s valid monitor. 4. Body mass index (BMI in kg/m2) in ISI units was measured using a reliable height and weight instrument to balance from digital body height and weight scale.

—

Countries

Oman

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026